Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. - Wikidata - wikimedia - TriplyDB

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

http://www.wikidata.org/entity/Q34747300

about

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms Targeting hypoxic response for cancer therapy Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.Evolutionary dynamics of carcinogenesis and why targeted therapy does not work.Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).Targeting hypoxic tumour cells to overcome metastasis.Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.Targeting hypoxia in the leukemia microenvironment Multimodality imaging of hypoxia in preclinical settings.Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer Docetaxel-encapsulating small-sized polymeric micelles with higher permeability and its efficacy on the orthotopic transplantation model of pancreatic ductal adenocarcinoma.Six degrees of separation: the oxygen effect in the development of radiosensitizers.Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.Modulation of the tumor vasculature and oxygenation to improve therapy Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model.Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic ranges Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.Single Amino Acid Switch between a Flavin-Dependent Dehalogenase and Nitroreductase.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.Targeting the metabolic microenvironment of tumors.Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.Enzymatic conversion of 6-nitroquinoline to the fluorophore 6-aminoquinoline selectively under hypoxic conditions.The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Orthotopic mouse models expressing fluorescent proteins for cancer drug discovery.Cytochrome P450-activated prodrugs.Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.The role of hypoxia in pancreatic cancer: a potential therapeutic target?Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia.Hypoxia-Sensitive Materials for Biomedical Applications.

P2860

Q26765247-C7838B3F-633D-4DC7-9BCB-46087DE22588 Q26767351-D7234740-688F-4FEA-98C3-CD9D6061DC09 Q26774750-235A40D6-EE8A-4ED3-A575-78BBB18E7277 Q29547558-D30A5DA4-5C3D-40FF-B55C-A2FD0245C64A Q33465375-12475D43-5098-48BF-92CD-F052EE0E9B92 Q33936624-6627522B-5A1D-4BE9-8997-F403B5EAC04F Q34005286-04BFF7DD-893A-48D5-94CF-71B837F21BD2 Q34061361-0073994D-51C6-4AB5-8745-97F05349221F Q34086671-900A0BDB-5FCB-4596-AA95-C157742C3ADF Q34257226-2415C4FD-05B3-43D3-A65B-4C95249B9AB3 Q34401785-35A94E7B-94A3-4F43-8BAA-1847D9114772 Q34605956-FDA0089D-CAC1-49BA-B197-92B9774F13DE Q34756921-74D89A05-DA04-4E58-A4AA-DEB3E6CBA44C Q34835853-CB25F7DA-BF15-4A01-A294-7AE62F246668 Q35116798-3D7D23BB-1421-4CFA-A729-DB54FB3E1261 Q35637224-1F3EDADC-6D7F-497B-A487-57CAC6279D16 Q35920685-69EE41EF-75D2-4875-97F7-F66F9009D7CA Q35993104-C4F6EC0F-8743-4D79-8DDD-A961D796019F Q36072569-E65E3E7A-4B76-453F-ACC6-48897D3651A4 Q36109993-052922A6-0EE6-4E15-9F6F-E826A347D04A Q36214623-F065D0E7-1649-41DD-A29E-55A5C172B69F Q36244673-C42E7E6A-824E-4DBB-88B5-547C7C7CA347 Q36286658-A36E2549-8710-4AFB-AEFC-D42F0E195740 Q36384273-27AFD014-563A-4876-A41C-908D6240DFF4 Q36444369-E5AE0BD7-F4C9-4977-9612-6214BC7525C5 Q36706902-7B38F7F9-BE9A-4E21-B19F-722150E65CD1 Q36938779-E4107140-D576-43E7-A7C2-1984DFD8F353 Q37229190-12A4DD56-A5D8-4895-A496-9B9DAC593FBE Q37283967-D7C7A7BB-4C22-4CDF-BA7B-9ED9DA42E97C Q37481367-E1D0849C-0F16-48F7-98F4-D2B0CB7301AC Q37700855-77D70974-2A98-4568-AAC5-93306A2A3461 Q37707385-7E1985FF-9F9C-42D0-A1FA-B9D3BBE3E61D Q37730301-E1E8A9AE-D575-4FFA-9E96-8C753D7E4C52 Q37884379-FFC0862A-1EAD-48D3-A049-CF9FE94999A5 Q38028571-D8931979-84F0-4F6A-93C1-95C7B762961B Q38077550-4F97F26D-B41A-4278-85C5-540A38A0C2E1 Q38120850-1923978C-F88C-4BD5-8961-4FF8D4102093 Q38631404-16FA5211-E3F5-48FA-979E-BBAAE610FB1A Q38725902-8CDFF828-F59B-4A66-B1B2-798A6A1BAD78 Q38754932-28DD7056-036C-4C3F-8911-3C5CFBB7676E

P2860

Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

http://www.wikidata.org/entity/Q34747300

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Potent and highly selective hy ...... mustards as anticancer drugs.

@ast

Potent and highly selective hy ...... mustards as anticancer drugs.

@en

Potent and highly selective hy ...... mustards as anticancer drugs.

@nl

type

label

Potent and highly selective hy ...... mustards as anticancer drugs.

@ast

Potent and highly selective hy ...... mustards as anticancer drugs.

@en

Potent and highly selective hy ...... mustards as anticancer drugs.

@nl

prefLabel

Potent and highly selective hy ...... mustards as anticancer drugs.

@ast

Potent and highly selective hy ...... mustards as anticancer drugs.

@en

Potent and highly selective hy ...... mustards as anticancer drugs.

@nl

P1433

Q34747300-ACA55FD4-063E-4F2B-9AE4-50E7B91E5F10

P1476

Q34747300-DC6D1B21-A38A-4461-B42A-C5190327039A

P2093

Q34747300-1307AC82-3B66-4E92-9821-6E291EAFCDED

Q34747300-1AEB2B0A-DD4C-4B6C-8E17-E8909C4B097C

Q34747300-27E4182A-A247-4039-816A-40E24F2B748D

Q34747300-28FEF997-0E46-4354-9B9D-025EF8E55E05

Q34747300-5FAD5619-1532-4DC3-9F98-2290960C0B76

Q34747300-75ED37A5-E5FD-4F8C-B8C6-EF652A82A51B

Q34747300-805B8FCB-7938-493F-AACE-6779D1B79A85

Q34747300-91896427-1B5E-4EC3-9C32-D1995D57F1E1

Q34747300-95AA7683-805C-44B9-8C57-D2BFB5275A89

Q34747300-9F5FCBDA-3C67-45E3-A004-9E2F12D080A3

P304

Q34747300-C72AC246-D22C-40F4-B000-BE5935053867

P31

Q34747300-41D375FB-650D-42B3-AD17-B3730661D39F

P356

Q34747300-204B13BB-90A8-4338-81C3-986C75695465

P407

Q34747300-8477D918-5853-4663-B69A-45FDAD7AA369

P433

Q34747300-48D1F81A-EDD2-4F80-A69A-D7D708FD9CE0

P478

Q34747300-544EAE09-F721-4596-8CD3-A4C53A1EBE23

P50

Q34747300-F833A034-6F35-4CAC-841C-F03267447C00

P577

Q34747300-FF9B2473-6440-4C94-9155-F41A2908C09D

P5875

Q34747300-50855B02-E011-4813-8192-B39A2E44CF67

P698

Q34747300-315085F1-A833-4CB8-AEEE-8804A4EBE27A

P921

Q34747300-5DCB1AD6-5C37-43BD-8782-880D6DF174D2

Q34747300-BFB767AC-B6B9-42B3-8542-427E9688F118

P356

P1433

Journal of Medicinal Chemistry

P1476

Potent and highly selective hy ...... e mustards as anticancer drugs

@en

P2093

Don Jung

http://www.w3.org/2001/XMLSchema#string

Gustavo Lorente

http://www.w3.org/2001/XMLSchema#string

Hailong Jiao

http://www.w3.org/2001/XMLSchema#string

Huaiyu Ma

http://www.w3.org/2001/XMLSchema#string

Jacob Kaizerman

http://www.w3.org/2001/XMLSchema#string

James W Evans

http://www.w3.org/2001/XMLSchema#string

Jian-Xin Duan

http://www.w3.org/2001/XMLSchema#string

Jinwei Wang

http://www.w3.org/2001/XMLSchema#string

Leslie Lan

http://www.w3.org/2001/XMLSchema#string

Mark Matteucci

http://www.w3.org/2001/XMLSchema#string

P304

2412-2420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM701028Q

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5593771

http://www.w3.org/2001/XMLSchema#string

P698

18257544

http://www.w3.org/2001/XMLSchema#string

P921